Premium Nahrungsergänzungsmittel | artgerecht

Immunoglobulin Replacement Therapy – Antibody Deficiency

Immunoglobulin replacement therapy supplies the body with antibodies from an external source to support a weakened immune system that cannot produce sufficient antibodies on its own.

Regular tips about health Regular tips about health

Things worth knowing about "Immunoglobulin Replacement Therapy"

Immunoglobulin replacement therapy supplies the body with antibodies from an external source to support a weakened immune system that cannot produce sufficient antibodies on its own.

What is Immunoglobulin Replacement Therapy?

Immunoglobulin replacement therapy is a medical treatment in which immunoglobulins – commonly known as antibodies – are administered from an external source. Antibodies are specialised proteins produced by the immune system to identify and neutralise pathogens such as bacteria and viruses. When the body is unable to produce a sufficient quantity of functional antibodies, immunoglobulin replacement therapy can provide the missing immune protection.

The immunoglobulins used in this therapy are derived from the pooled blood plasma of thousands of healthy donors. They are carefully purified and processed for medical use and consist primarily of Immunoglobulin G (IgG), the most abundant antibody type in human blood.

Indications

Immunoglobulin replacement therapy is primarily used in conditions where the immune system fails to produce adequate functional antibodies. These conditions are collectively referred to as antibody deficiency syndromes or hypogammaglobulinaemia.

Primary immunodeficiencies: Inherited conditions such as Common Variable Immune Deficiency (CVID), X-linked agammaglobulinaemia (Bruton disease), or other primary antibody deficiency disorders.
Secondary immunodeficiencies: Acquired antibody deficiencies resulting from diseases such as chronic lymphocytic leukaemia (CLL), multiple myeloma, or following stem cell transplantation.
Hypogammaglobulinaemia due to immunosuppressive therapy: Patients receiving immunosuppressive medications – for example after organ transplantation – may develop significant antibody deficiency.

Routes of Administration

Immunoglobulin replacement therapy can be administered via two main routes:

Intravenous Immunoglobulins (IVIG)

With intravenous administration, immunoglobulins are infused directly into a vein, typically in a hospital or specialist clinic. Infusions are usually given every 3 to 4 weeks. This route delivers high concentrations of antibodies into the bloodstream rapidly.

Subcutaneous Immunoglobulins (SCIG)

With subcutaneous administration, immunoglobulins are injected beneath the skin. This method can often be performed by the patient at home, typically on a weekly basis or in smaller daily doses. It provides a more stable antibody level in the blood and is considered more convenient by many patients.

Dosage

Dosing is individualised and based on several factors:

Body weight of the patient (typically 0.4–0.6 g/kg body weight per month for replacement therapy),
measured serum IgG trough levels,
frequency and severity of infections,
clinical response to therapy.

The therapeutic goal is to maintain the IgG trough level (the lowest level before the next dose) at a protective concentration that significantly reduces the rate of infections.

Side Effects

Immunoglobulin replacement therapy is generally well tolerated. Possible side effects include:

Common side effects: Headache, chills, fever, nausea, fatigue, and local reactions at the injection or infusion site.
Rare side effects: Allergic reactions including severe anaphylactic shock (very rare), renal impairment, thrombosis, or aseptic meningitis.
Patients with selective IgA deficiency are at increased risk of severe allergic reactions, as they may develop antibodies against IgA present in the preparation.

Safety and Quality of Preparations

Modern immunoglobulin preparations undergo rigorous manufacturing and safety processes, including multiple virus inactivation steps. The risk of transmitting infectious diseases through immunoglobulin products is considered very low today. Production is governed by strict European medicines regulations.

Monitoring and Follow-Up

Patients on immunoglobulin replacement therapy are regularly monitored by their healthcare team. Key aspects of monitoring include checking IgG trough levels in the blood, documenting infection frequency and severity, and monitoring liver and kidney function to adjust dosing as needed.

References

European Society for Immunodeficiencies (ESID): Guidelines for the Use of Immunoglobulin Replacement Therapy (2023). Available at: https://esid.org
Bonilla FA et al. - Practice parameter for the diagnosis and management of primary immunodeficiency. Journal of Allergy and Clinical Immunology, 2015; 136(5):1186-1205. PubMed PMID: 26371839.
Lejtenyi D, Mazer B - Consistency of dose and product type in patients receiving immunoglobulin replacement therapy. Journal of Allergy and Clinical Immunology, 2008; 122(6):1225-1226.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.